Navigation Links
Newsbriefs from the July issue of the journal Chest
Date:7/4/2011

COMBINATION ANTITHROMBOTIC THERAPY MAY INCREASE BLEEDING RISK

A new study suggests that the use of combination antithrombotic therapy may increase the risk of clinically relevant bleeding in patients with atrial fibrillation (AF). Researchers from the United Kingdom, the Netherlands, and France compared outcomes in 3,728 patients with AF receiving anticoagulation alone and 848 patients with AF receiving combination antithrombotic therapy (anticoagulant and antiplatelet therapy). Results showed that patients receiving combination therapy had a 2.3-fold increased risk of clinically relevant bleeding compared with anticoagulation therapy alone. Combination antithrombotic therapy also does not appear to reduce the risk of stroke. Results suggest that combination antithrombotic treatment is justified only in patients where the benefit of adding antiplatelet therapy to anticoagulant therapy outweighs bleeding risk. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):146-155.


IDENTIFYING PULMONARY ARTERIAL HYPERTENSION EARLY REMAINS PROBLEMATIC

One in five patients diagnosed with pulmonary arterial hypertension (PAH) in the United States report symptoms for more than 2 years before diagnosis. PAH is a progressive and fatal disorder, and the disease is often advanced when recognized, especially in younger patients. Researchers from Intermountain Medical Center, the University of California, University of Pennsylvania, Baylor College of Medicine, Boston University, and Mayo Clinic studied 2,967 adult patients enrolled in the Registry to Evaluate Early Long-term PAH Disease Management (REVEAL), for an 18-month period. In 21.1% of patients, symptoms were experienced for more than two years before PAH was recognized. History of obstructive airways disease and sleep apnea were independently associated with delayed PAH recognition. Despite progress in understanding the cellular and genetic basis of PAH, researchers found that the onset of PAH before age 36 years was associated with the greatest likelihood of delayed disease recognition, especially in individuals with histories of common respiratory disorders. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):19-26.


INDACATEROL MAY REDUCE EXACERBATIONS IN PATIENTS WITH MODERATE TO SEVERE COPD

New research shows that indacaterol is effective and well tolerated for patients with moderate to severe chronic obstructive pulmonary disease (COPD). Researchers at the University Health Network, Asthma and Airway Centre, in Toronto, ON, Canada; the University of Nebraska Medical Center; and Novartis evaluated the safety and tolerability of indacaterol, a once-daily, inhaled β2-agonist, compared with a placebo in 415 patients with moderate to severe COPD. Over a 1-year period, researchers found that therapy with indacaterol led to significant reductions in COPD exacerbations and as-needed albuterol use, and it was well tolerated. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):68-75.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. Newsbriefs from the April issue of the journal Chest
2. Emotional, Behavioral Issues Affect Many Kids in Foster Care
3. Breast Cancer Plus Other Health Issues Linked to Worse Outcomes
4. FDA Issues New Rules on Sunscreens
5. Ovarian cancer cells bully their way through tissue
6. Chest journal news briefs -- June 2011 issue
7. Hartford Program issues geriatric social work awards, forms VA partnership
8. ASGE and SHEA issue updated multisociety guideline on reprocessing flexible gastrointestinal endoscopes
9. Childhood Cancer Therapies Tied to Gastrointestinal Issues
10. MetLife Foundations grant bolsters media coverage for aging issues
11. Experts Issue Top 5 List for Better Primary Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in the health care ... leaders in the nursing and health care industry. It also provides insight to the ... University. , As the nursing industry is coming out of one of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology: